Boston Partners Acquires 16,601 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Boston Partners raised its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 1.3% in the 4th quarter, Holdings Channel.com reports. The fund owned 1,291,868 shares of the biopharmaceutical company’s stock after buying an additional 16,601 shares during the period. Boston Partners’ holdings in Catalyst Pharmaceuticals were worth $27,325,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the business. Intech Investment Management LLC grew its stake in shares of Catalyst Pharmaceuticals by 103.2% during the 4th quarter. Intech Investment Management LLC now owns 65,826 shares of the biopharmaceutical company’s stock worth $1,374,000 after acquiring an additional 33,431 shares in the last quarter. Cibc World Markets Corp bought a new position in shares of Catalyst Pharmaceuticals during the 4th quarter worth approximately $218,000. Globeflex Capital L P grew its stake in shares of Catalyst Pharmaceuticals by 319.8% during the 4th quarter. Globeflex Capital L P now owns 194,786 shares of the biopharmaceutical company’s stock worth $4,065,000 after acquiring an additional 148,388 shares in the last quarter. Natixis Advisors LLC grew its stake in shares of Catalyst Pharmaceuticals by 29.8% during the 4th quarter. Natixis Advisors LLC now owns 59,253 shares of the biopharmaceutical company’s stock worth $1,237,000 after acquiring an additional 13,616 shares in the last quarter. Finally, Commonwealth Equity Services LLC grew its stake in shares of Catalyst Pharmaceuticals by 133.1% in the fourth quarter. Commonwealth Equity Services LLC now owns 39,331 shares of the biopharmaceutical company’s stock valued at $821,000 after buying an additional 22,455 shares in the last quarter. 79.22% of the stock is owned by institutional investors.

Insider Activity at Catalyst Pharmaceuticals

In related news, insider Gary Ingenito sold 44,904 shares of the company’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total value of $991,929.36. Following the transaction, the insider now directly owns 68,873 shares in the company, valued at approximately $1,521,404.57. This represents a 39.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Brian Elsbernd sold 62,975 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the transaction, the insider now owns 188,564 shares in the company, valued at $4,333,200.72. This trade represents a 25.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by corporate insiders.

Catalyst Pharmaceuticals Stock Performance

CPRX opened at $22.60 on Thursday. The stock has a fifty day moving average of $22.34 and a 200-day moving average of $21.57. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $14.47 and a fifty-two week high of $24.64. The company has a market capitalization of $2.74 billion, a P/E ratio of 19.15, a P/E/G ratio of 3.31 and a beta of 0.84.

Wall Street Analysts Forecast Growth

CPRX has been the subject of several analyst reports. Stephens reissued an “overweight” rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. Bank of America reissued a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Robert W. Baird raised their target price on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, March 3rd. Finally, StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $32.50.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.